Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis

Reuters10-01

<a href="https://laohu8.com/S/EVFM">Evofem Biosciences</a>' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis

**Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates $(UAE)$ Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis $(BV)$ and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2572531937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572531937","market":"nz","top_or_hot":-1,"title":"Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a>' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates <a href=\"https://laohu8.com/S/UAE\">$(UAE)$</a> Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis <a href=\"https://laohu8.com/S/BV\">$(BV)$</a> and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-01 20:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a>' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates <a href=\"https://laohu8.com/S/UAE\">$(UAE)$</a> Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis <a href=\"https://laohu8.com/S/BV\">$(BV)$</a> and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVFM","symbol_name":"Evofem Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL88mtnb:1","article_id":"2572531937","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572531937","pubTimestamp":1759322849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates  Ministry of Health and Prevention for SOLOSEC  2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis  and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVFM":"Evofem Biosciences, Inc.","BK4007":"制药","BK4584":"避孕概念"},"translate_title":"Evofem Biosciences的SOLOSEC®阿联酋正在接受治疗细菌性阴道病和滴虫病的监管审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":0.9},"content_text":"Evofem Biosciences' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n    \n\n        **Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates $(UAE)$ Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis $(BV)$ and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572531937","isCrawlerRequest":true}